Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cingulate Inc

CING ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$5.23

▼ -0.19%

Market Cap $76.05M · Vol 18.31K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$76.05M

Micro Cap

Div Yield

N/A

EPS Growth

+47.97%

YoY

RSI (14)

53.06

Momentum

Beta

-0.94

vs Market

52W High

$11.83

55.71% below

52W Low

$3.19

64.26% above

Volume

18.31K

Avg 29.78K

P/B

12.54

Price-to-book

ROE

N/A

Return on equity

Free Float

71.68%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cingulate Inc (CING) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CING pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.16%

-5.77%

+4.81%

-29.13%

YTD

+20.51%

+47.74%

-97.13%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-22,449,910.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-149.97% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	12.54
P/FCF	N/A
EPS Growth	+47.97%
Outstanding Shares	14.54M

Technical Indicators

50-Day SMA	$5.04
200-Day SMA	$5.36
RSI (14)	53.06
Beta	-0.94
52-Week High	$11.83
52-Week Low	$3.19

Volume Today	18.31K
Avg Daily Volume (30D)	29.78K
Relative Volume	0.61x
Volatility (10D)	25.71
Volatility (30D)	39.48
Free Float	71.68%

Analyst Consensus

BUY

Current Price $5.23

Mean Target $21.20

52W Low$3.19 52W High$11.83

Current

Target

$3.19 $11.83

Current Analyst target

+305.35% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG012G40NT6

ISINUS17248W3034

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.59% ONC BeOne Medicines AG +4.23% 068270.KS Celltrion, Inc. +1.11% MEDP Medpace Holdings, Inc. +1.94% ABVX Abivax SA -1.51%

Company Profile

Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.